Keywords: ProStrakan, GTx, Asset purchase, Fareston, Breast cancer, Kyowa Hakko, Orion
ProStrakan buys GTx' US rights to breast cancer drug Fareston
Article | 02 October 2012
Scotland-based ProStrakan, a subsidiary of Japanese drugmaker Kyowa Hakko Kirin (TYO: 4151), has acquired exclusive US commercialization rights to Fareston (toremifene ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- Boehringer Ingelheim transitions to propellant-free Combivent Respimat; names new BMD member
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Neovacs moving forward in rheumatoid arthritis, say analysts
